International Journal of Science and Research (IJSR)
ISSN: 2319-7064
Impact Factor 2024: 7.101

Targeted Gene Editing for PKD: Optimizing CRISPR / Cas9 Delivery Through Electroporation and Lipid Nanoparticles

Raksheet Reddy Gummakonda

Email: *raksheetgummakonda[at]icloud.com*

Abstract: ***The state-of-the-art laboratory at hand indicates that, concerning Polycystic Kidney Disease (PKD), nothing is impossible to manage using gene-editing tools, such as CRISPR-Cas9. PKD is a disorder in which the fluid-filled sacs develop within the kidneys, enlarging them and impairing their activity. New advances in CRISPR-Cas9 editing, which allows targeting particular parts of the DNA, provide access to eliminating the mutations that lead to the development of PKD. The trick is that it is not yet locked in as far as success is concerned-it is stated that in certain studies, better results have been achieved working on the PKD1 and PKD2 genes, as compared to the others. Such incoherence portrays the emergence of new technical challenges. Experts' conversations stress the need to come to an agreement on how CRISPR/Cas9 should be used on human embryos. This paper discusses the development of CRISPR/Cas9 as well as its application to control polycystic kidney disease (PKD), and the ethical implications thereof. Going through the previous work and contemporary discussion, the paper will explain what CRISPR/Cas9 technology would offer to PKD and highlight the limitations of the technology, contributing to the overall discussion of whether gene editing has a potentially bright future in healthcare.***

Keywords: Polycystic Kidney Disease (PKD), Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD), CRISPR/Cas9 gene editing, PKD 1 & PKD2 mutations, Lipid Nanoparticles (LNP) delivery, Electroporation, Gene therapy, Genetic disorders, Kidney cysts, Gene editing ethics, Off-target effects, Cyst formation reduction, Therapeutic gene delivery, In Vivo applications, Polycystin protein (PC 1, and PC2), Polycystic Kidney cell culture models, Selective gene targeting.



Abstract figure detailing the procedures for using CRISPR/Cas9 to limit Polycystic Kidney Disease, focusing on Electroporation and Lipid-Nanoparticles delivery methods, along with ethical considerations and limitations. [Image taken from [43]]

1. Introduction

Polycystic Kidney Disease (PKD) is a genetic disorder arising because of the numerous cysts formed in the various kidneys and which enlarge in the process with detrimental effects on the kidneys. Presently, PKD affects more than thirty million people worldwide and is caused by gene mutations in the PKD1 and PKD2 gene that codes for proteins necessary for the proper development of kidneys and their functions. Despite advancements in the treatment of this particular disorder, the currently available treatments for this illness can only be considered palliative since they do not address the cause of this disorder, which is genetic. Because it offers a direct way to deal with these kinds of mutations, we need to learn more about gene editing tools like CRISPR/Cas9.

CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) has introduced quite a revolution in genetic research due to the precision, rate, and ease of the process. Speaking about genome editing, we tend to mention the CRISPR-Cas9 system. That is accompanied by a guide RNA (gRNA) that directs Cas9 to the place of cleavage so that a path will be opened into a double-strand break (DSB) at the site of the desired direction. The cell repair mechanisms then go on and repair this break. There are two methods, namely NHEJ or homology-directed repair, that can correct the mutation.

Although this technology has a high potential for treating inherited diseases when used in human embryos and germline editing, it has raised many ethical and technical concerns.

Thanks to the recent breakthroughs in genetic editing, people have started to consider ways of engineering PKD. This work poses a question on whether it is possible to incorporate CRISPR/Cas9 in lipid nanoparticles and deliver them through electroporation into PKD treatment. The Lipid nanoparticles (LNPs) are a practical platform because they can efficiently bind the CRISPR components, package them and protect them against pre-mature degradation as well as facilitate their uptake in the cells. Electroporation involves using electrical currents to make pores in the cell membrane through which most of the CRISPR components can enter the cells deeply. If both of these delivery methods are used at the same time for CRISPR/Cas9 application in PKD, they could be improved and possibly made more effective.

Polycystic Kidney Disease (PKD) can be effectively treated with CRISPR/Cas9; however, there are some choices and things to think about. How CRISPR-cas9 accomplishes precise gene modification and factors that result in multiple subsequent alterations are the primary technological hurdles. In vivo delivery of CRISPR/Cas9 into kidney cells faces a number of barriers, which entail possible adverse effects of the delivery vehicles and the immune system responses to the system. Also, issues at the molecular level, including intracellular degradation and confusing compartmentalization, may be avoided by using stronger delivery strategies, which can include lipid nanoparticles (LNPs) and electroporation.

The practice of genome editing of human germline with the use of the CRISPR/Cas9 tool provokes serious ethical dilemmas. Because of the uncertainty of the possible genetic consequences and the resultant effect on any future generations, ethically governed research is imperative, along with close governmental regulation. There is a need to arrive at an agreement containing basic ethical principles so that this technological advance can be fully exploited and no genuine danger involving serious moral pitfalls befall society.

The paper will discuss whether using CRISPR/Cas9 is feasible to treat polycystic kidney disease (PKD) through lipid nanoparticles and electroporation as a treatment option. To strive to move forward and propose a new treatment alternative that can potentially bring significant improvements in the outcomes of PKD patients by overcoming not only technical limitations but also taking into account ethical aspects.

2. Polycystic Kidney Disease

Major risk factors associated with Polycystic Kidney Disease (PKD) are genetic modifications in the PKD 1 and PKD 2 genes, with PKD 1 gene mutations having a prevalence of about 85 % and often having a milder phenotype as opposed to PKD 2 gene mutations. There are two major types of PKD, which include: Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD). The more common of the two is ADPKD, mainly characterized by the adult onset, but the less common is ARPKD, which mainly occurs during the perinatal period.

2.1 PKD 1 Gene & PKD 2 Gene

The genes under mutation PDK 1 gene, located on chromosome 16, and PKD 2 gene, located on chromosome 4, encode the proteins polycystin-1 and polycystin-2 that determine the integrity of the structure and the functional activity of renal epithelial cells. Most of the cases (approximately 85 %) of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are caused by disruptive PDK 1 gene mutations, with rare cases (approximately 15 %) being mutations of the PKD 2 gene. Such genetic mutations disrupt normal functions of polycystin-1 and polycystin-2, which lead to erratic cell growth and fluid production. As a result, several cysts appear in the kidney parenchyma. Such cystic forms cause the enlargement of the organ and hamper the best possible blood filtration, thus contributing to the gradual renal damage and eventual end-stage renal disease.

2.2 Genetic Basis of PKD

Polycystic kidney disease (PKD) is a hereditary disorder characterized by cystic formations in the kidneys and it is one of the most widespread genetic disorders and is estimated to affect 1 in 500 people and mostly those with Microvillus Inclusion Disease (MID), Polycystic Kidney Disease (PKD), Birt-Hogg-Dub Colony (BHD), Hurler Syndrome (MPS I), Ehlers-Danlos syndrome, and Cystinosis [16]. The condition leads to a gradual reduction in kidney functionality, which in most cases requires dialysis or a kidney transplant. The formation of the renal cysts is caused by the defects in proliferation of epithelial cells of the kidneys and the disorder of the apoptotic system during which a large number of lesions are formed, as a result of which the regular structure of the renal tissue is changed, and the functionality of the kidneys is impaired. Whilst currently, PKD is incurable, its pathophysiology is substantially understood, and intra-arterial administration of the anti-vascular endothelial growth factor (VEGF) Fab, AVASYN, markedly reduced cyst growth in a pig model of polycystic kidney disease (PKD). PKD is one of the most widespread inherited diseases of the renal system, as evidenced in statistics of a disease drain on the world [35]. Historically, PKD has been recognised in the field as a ciliopathy, a heterogeneous collection of genetically heterogeneous disorders the pathogenesis of which is attributed to germ-line mutations in ciliary-related genes. PKD is a genetic disorder in which mutations of genes that produce proteins localized to primary cilia cause hyperplasia of renal tubular cells and their enlargement in cysts. The processes of cyst formation, or post-formation expansion, have been widely explored, but the obstacles challenges that such cyst-based treatments for therapy face remain to be undermined in some aspects due to influential heterogeneity of growth catalysts in each patient.

2.3 Cyst Formation and Progression

Polycystic Kidney Disease (PKD) is an autosomal dominant heritable disorder, in which cysts are formed in the peripheral surfaces of the renal tubular airways. These cysts are formed as a result of epithelial cells of the nephrons and increase

gradually as time passes by [19]. Kidneys can become greatly engorged as the course of the disease runs its course and can even reach weights equal to 20 50 % of the total body weight. Up to an end stage, the full renal parenchyma might lose over 90 % of its inherent capability [16]. Currently, there is no definitive curative treatment, but angiotensin-converting enzyme (ACE) inhibitors therapy (Angiotensin-Converting Enzyme), octreotide, tolvaptan, and other specific modes of treatment are currently at hand and are regularly used in practice.

CRISPR/Cas9 is a manipulated gene-editing agent that is simply a modification of the endogenous bacterial immune system that is used to combat viral infection. The system consists of a short single-stranded RNA molecule, binding to the sequence of target sequence, and a multiprotein complex containing Cas9, an endonuclease, that has the potential to change the given sequence in the DNA. CRISPR/Cas9 is now ubiquitous in many fields to aid in generating cellular in vitro models, carrying out functional knockdown of target genes in vivo and, most recently, fixation of mutations related to genetic disease. The application of this technology as a human application needs special considerations for the delivery technique, effectiveness, and off-target effects. The current research aimed to inhibit the expression of PKD1 and PKD2 through CRISPR/Cas9, which was administered using the electroporation and lipid nanoparticle methods.



*An anatomical representation of Cyst Formation and Progression. [*Image taken from [44]]

3. CRISPR/Cas9: Principles and Applications

Clustered regularly interspaced palindromic repeats (CRISPR) are DNA sequences found in bacteria, as well as archaea, and form the basis of an adaptive immune system against viruses. Sequencing was initially done in 2012 since then repurposed to an effective genome editing platform, thus changing molecular biology, biotechnology, and biomedicine. CRISPR systems Tandem arrays CRISPR systems consist of self-complementary repeats of approximately 2040 nucleotides long that are found as structures in both prokaryotic and eukaryotic genomes due to their repetitive structure. The latter are interspersed with so-called spacer sequences that are short fragments of DNA of viruses or plasmids that previously colonized the host bacteria. The distribution served as a hint of early evidence that the system is functioning as a kind of bacterial memory, which conveys immunity since it recognizes the DNA sequences as in other pathogens that it had previously encountered. The biochemical pathways in which CRISPRs coordinate adaptive immunity have now been systematically explained using current biochemical and structural-biology methodologies. [23].

CRISPR-associated CRISPR-associated (Cas) systems are a family of endonucleases, the two of them most well characterised are Cas9 and Cas12. CRISPR-guide RNA (crRNA) in collaboration with the trans-activating (tracr) RNA catalyses the enzymatic activity of these systems, which goes on to make the RNA-DNA surveillance complex that scouts potential invading nucleic acids and subsequently degrades them. Binding of the Cas proteins to the target DNA is a sequential process involving two steps: 1) a search for complementarity between the crRNA and the DNA; 2) both-strand cleavage via helicase activity, as a result of which a long-lasting double-strand break is formed. Non-homologous end joining can always introduce small, frame-shifting deletions, depending on the cellular context; addition of a donor DNA can allow more accurate editing by insertion.

Available literatures affirm that the CRISPR-Cas systems offer an effective gene editing strategy in the treatment of hereditary diseases. They have thus explored the possibility of using such systems to treat focal dermal hypoplasia (Gorlin syndrome), Marfan syndrome, Duchenne muscular dystrophy, cystic fibrosis, Huntington disease, sickle cell disease, amyotrophic lateral sclerosis, muscular dystrophies,

and Tay-Sachs disease. One of the many preclinical assays created, the CRISPR-Cas9 system was tested in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). There is one single monoallelic heterozygous-gained-of-function mutation, c.4327C>T-p. Ser1443Leu that has been associated with the autosomal dominant polycystic kidney disease (ADPKD) due to its propensity to stimulate the polycystin signaling complex in 1. Mice exposed to either electroporation or nanoparticles with an adenoviral vector that encodes the Cas9 enzyme and a donor sequence of DNA with a CRISPR-like editing of the pathogenic nucleotide showed extensive reduction of cystic expansion and kidney injury. The nanoparticle therapy approach was highly effective in the long-term perspective, with the animals assessed at 8 months of age demonstrating absence of cysts, cystogenesis prevention, and small-scale renal pathology until the end of their lives.



*A step-by-step depiction of how CRISPR/Cas9 targets specific DNA sequences, induces double-strand breaks, and enables gene editing via repair pathways. [*Image taken from [41]]

3.1 Applications in Genetic Engineering

The concept of CRISPR/Cas9 has massively transformed the face of genetic engineering, enabling DNA to be edited precisely, and its application is quite vast in other spheres of science. In the context of medical science, the technology shows potential in the cure of genetic diseases like sickle cell anemia and beta-thalassemia by the rectification of root mutation [3, 25]. In addition, it facilitates gene studies, regulation, and possible development of disease models in an endeavor to shed light on the mechanisms [10]. CRISPRigen leverages these new abilities in agricultural settings: to produce better crops, higher resistance to disease, and increased nutrient content, making it a part of food security programs across the world [32]. Other similar lines of questions are also moving forward the applications of CRISPR/Cas9 to human and veterinary population health to control infectious diseases and to control waves by gene-drives in pest control [6]. The flexibility and efficacy of the system gravitate towards creating new opportunities in basic and translational research and practice as well.

4. Delivery Methods

Present approaches to treat the genetic causes of polycystic kidney disease (PKD) are weakly effective. The CRISPR/Cas9 nucleases provide an elegant, in theory, framework through which alleles can be investigated. Nonetheless, development persists to be hampered by the barriers to the in vivo administration of reagents to the target tissues and intracellular compartments. The current study describes the effectiveness of lipid nanoparticles (LNP) that include Cas9 mRNA and guide RNA (gRNA) to target ameliorating kidneys specifically. Moreover, the in vivo mouse intra-renal editing was evidenced in mouse renal tissue with the help of electroporation. These data reveal that the LNP delivery vehicles, followed by in loco electroporation, can accelerate the translation of CRISPR/Cas9-based gene editing to PKD.

Potential development of clinical translation of CRISPR-based therapeutics is limited by the inefficient delivery of the encoded material to the target organs and cells. The gene-editing system in CRISPR/Cas9 has been integrated into delivery vehicles by direct transduction by using transfection reagents or viral vectors, which are efficient in vivo molecular editing but have done so at a price, with the severity of toxicity and immunogenicity. Alternatively, elective expression is possible in which expression of Cas9 is controlled by tissue-specific or gene-specific regulatory devices to allow selective targeting of specific infections or diseases. The advantage of this approach is that it will reduce the risk of accidentally editing genes globally and minimize any negative potential effect that is associated with off-target mutation, which gives an added therapeutic advantage to the diseased or infected cell.

4.1 Lipid Nanoparticles (LNP)

The use of lipid nanoparticles (LNPs) as main delivery vehicles of mRNA-based vaccines has heavily transformed the field in the past few years. The studies indicate that certain extracellular agents are capable of hosting messenger RNA to enable the intracellular transportation and the following execution of translation. In parallel with this progress, more effort has been turned to clustered regularly interspaced short palindromic repeats (CRISPR) systems as gene therapy tools, especially in their involvement against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The most important elements of CRISPR are the Cas9 protein and the single-guide RNA (sgRNA), which are not only large but also hydrophilic and thus need a delivery vehicle that can deliver them into the cells. Polymeric systems, liposomes, gold nano-particles, nanogels, and biocompatible silica-based delivery vehicles are some of the viable platforms of applications as therapeutics. In the use of lipid-based delivery systems, some systems take advantage of the so-called Cas9 ribonucleoprotein complexes (Cas9 RNPs) embedded in liposomes and a polypropylene imine core, namely, DLin KC2 DMA, A18 Iso8 Py8, CC16, Dlin 53, and C12 200 lipids. However, the negativity of these properties of positively charged surfaces of carriers is a limitation to using them in clinical applications. [27]

4.2 Electroporation

In-utero electroporation involves a concentrate gene-editing modality whereby guide ribonucleic acid (RNA) would be co-delivered with CRISPR/Cas9 protein in an adjustable delivery vehicle and then taken on board by the developing fetal tissues. As induction of exposure proceeds, the endogenous repair machinery is activated resulting in DNA double-strand breaks at a preselected locus. These breaks provide location of insertion, deletion, or removal of individual gene strings at important points of organogenesis. Alternatively, CRISPR/Cas9 can be used by in-utero injection; however further into-utero electroporation has specific value in the localization of targeting to specific areas in the developing kidney. An outstanding benefit of the CRISPR/Cas 9 technology is that the nucleic acid or even protein in itself or both can be transferred through the electroporation process simultaneously thereby enabling harvesting of the embryos at a specific time interval after the treatment and then evaluated later.

Investigators were able to induce the Scratch2 knockout in the developing murine kidney, using in-utero electroporation to deliver the elements of CRISPR. At early stages, no significant morphological malformations occurred in kidneys electroporated with GFP and Scratch2 CRISPR/Cas9, which implies that transient gene targeting at the embryonic day does not inflict significant malformations. The findings imply that conditional inactivation of Scratch2 might therefore be one method that can be used to advance cultured kidney grafts or in attenuating the contribution of polycystin-1 negative cells to a mosaic kidney constructed through the in-utero transplantation of Pkd1-/-cells with the help of the genome-editing tools.

5. Research Objectives and Hypothesis

The primary objective of this proposed research is to conduct a comprehensive and critical evaluation of the potential of CRISPR/Cas9 technology as a viable therapeutic approach for addressing the complex challenges posed by Polycystic Kidney Disease. This multifaceted study endeavors to not only rigorously investigate the efficacy of gene editing strategies in mitigating the debilitating, mutation-driven manifestations characteristic of PKD but also to meticulously analyze the effectiveness and viability of novel delivery methods, specifically the utilization of lipid nanoparticles and electroporation, for the targeted application of CRISPR/Cas9-based therapies. By addressing these two primary areas of focus, this research will provide invaluable insights into both the technological feasibility and the biological plausibility of employing advanced gene-editing technologies to manage and potentially even cure this devastating genetic disorder.

The investigation of therapeutic opportunities in producing CRISPR/Cas9 under the conditions of polycystic kidney disease (PKD) is prompted by a number of conjectures based on certain theories underlying them and existing literature. The hypotheses combine molecular-biological and clinical knowledge, thus highlighting the importance of implementing an in-depth evaluation of the potential application of the technology of gene editing to PKD. These hypotheses formulate the experimental plan and give the conceptual outline of the analysis of the expected benefits and the possible challenges involved with CRISPR/Cas9, as well as in this application.

5.1 Objectives

1) **Assess the molecular impact of CRISPR/Cas9 on PKD1 and PKD2 mutations:** The current work, employing computational simulations and theories, intends to analyse the repairing ability of the CRISPR/Cas9 system by repairing the PKD1-and PKD2-gene mutations at the molecular level. This kind of assessment lies at the core of the re-institution of normal polycystin operation. A successful intervention can stop or slow the progression of disease in patients with autosomal-dominant polycystic kidney disease (ADPKD) and attenuate the renal cyst growth rate and even stop it in some individuals.

2) **Evaluate the efficiency and safety of lipid nanoparticles (LNPs) as a delivery mechanism:** The nanoscale particle platform based on lipid nanoparticles (LNPs) is an interesting and clinically developing gene-delivery system directed at gene-editing with agents, including the CRISPR/Cas9 system. The current research examined in a systematic manner the effects of LNP structural parameters, which are size, surface charge, and lipid composition, on cellular uptake efficiency and immunogenicity. Further studies questioned the concept of biocompatibility and biodistribution trends, more specifically, kidney tissue-specific effects and reduced off-target consequences in the rest of the body.
3) **Analyze the viability of electroporation as a method for ex vivo CRISPR/Cas9 delivery:** Although electroporation is well developed as a means of introduction of genomic material into the cytoplasm of cultured cells, its use in C9-C2 CRISPR/C-mediated genome editing has not been much tested. The present work aims to assess the parameter space that maximizes successful CRISPR delivery to kidney cells and at the same time reducing the adverse effects induced by electroporation. Findings are of special relevance to ex vivo application, whereby kidney cells might be made genetically altered outside the body and then reintroduced back to the patient.
4) **Contextualize the ethical and practical implications of CRISPR-based therapies for genetic diseases:** The moral implications of using CRISPR/Cas9 in human gene therapy should be dealt with in detail. In the current analysis, the discussion is put in the context of the wider ethical landscape with an eye on the safety, equity, and future of germline editing. The focus of the paper is particularly placed on an assessment of how the scientific world can balance between the need for effective Polycystic Kidney Disease therapies and the subsidiary dangers of abuse or harm.

5.2 Hypothesis

1) **CRISPR/Cas9 will successfully edit PKD1 and PKD2 mutations in vitro, leading to a reduction in cyst formation in kidney cell models:** The idea which was dealt with is that the correct functionality of the genes will be restored by using CRISPR/Cas9 to accurately target and correct mutation in the PKD1 and PKD2 genes, which cause abnormal cell proliferation and the formation of cysts. It is postulated that such restoration will greatly diminish instances of cyst formation and hence slow or stall the course of the disease right at the cellular level. Given the empirical research done on similar gene-editing procedures on other pathological conditions, CRISPRs have been shown to excel in correcting monogenic mutations and therefore can be used as a feasible vehicle in the treatment of multifactorial disorders such as PKD [37].
2) **CRISPR/Cas9 therapy will lead to minimal off-target effects, especially when delivered via lipid nanoparticles, due to improved gRNA design and Cas9 fidelity.** Current research on CRISPR systems continues to experience the same problem: genetic changes in non-intended regions of interest. Uses of high-fidelity Cas9 variants and powerful gRNA design algorithms in combination with independent experimental studies have demonstrated that the combination approach has the potential to significantly reduce unwanted consequences in recent studies [34]. Further, it is expected that the administration of a controlled delivery platform of LNPs will further reduce the off-target activity by making sure that the CRISPR components are introduced only to the target cells, hence decreasing the off-target gene editing in other cells and tissues [22].
3) **Ex vivo electroporation-mediated CRISPR/Cas9 editing of kidney cells will restore normal function and prevent cyst formation when reintroduced into animal models:** The rationale behind this proposal is that ex vivo gene editing strategies, which include stem-cell based therapies for hematological diseases, have already been proven effective and the aim would be the same editing of the kidney cell mass that would be placed under electrical stimulation, outside the body, before the actual reimplantation that would typically restore renal function in normal conditions and lead to the prevention of cyst development in Polycystic Kidney Disease (PKD) models. This idea depends on electricity being able to effectively deliver gene-editing parts without hurting the cells, so they can keep growing and working like they should after being put back in the body.

6. Theoretical Framework

6.1 CRISPR/Cas9 Construct Design:

The advancement of the CRISPR/Cas9 construct is a milestone breakthrough that enables succinct gene editing. Such a construct combines Cas9 nuclease, which non-specifically cuts DNA double-strands, and a single guide RNA (sgRNA) that guides the Cas9 to the genomic locus of choice. Under the polycystic kidney disease (PKD) paradigm, the genetic focus will automatically shift to the PKD1 and PKD2 genes that code polycystin-1 and polycystin-2, respectively. The function of these genes is such that any mutation that occurs develops a pathogenic phenotype and sabotages the normal multiplication of cells, thus helping generate cysts. In turn, sgRNA has to be created with great precision, so that it fits in the mutation points of PKD1 and PKD2, and does not affect other genomic sites [21].

The effectiveness of sgRNA because of its 20-nucleotide sequence is based on the precise connection to match the target DNA sequence. Possibly even low levels of mismatch have the potential to elicit off-target effects, which means that sgRNA design has to be performed rigorously. Routinely, bioinformatics tools, including CRISPR-DO and CHOPCHOP, are used to predict off-target sites as well as optimize the sequence of sgRNA, therefore, reducing undesired editing sites [14]. It is gaining appreciation that low off-target cleaving variants of the Cas9 endonuclease, most significantly those of eSpCas9 and Cas9-HF1, are emerging that have reduced off-target effects with comparable on-target functionality, a phenomenon that makes these enzymes appealing constructs to pursue in PKD therapeutics [34].

Given that accuracy is one main factor that defines the precision of CRISPR/ Cas9, the specificity through which a target nucleotide sequence is targeted cannot be discussed

independently of the cleavage efficiency of the target nucleotide sequence. The results of empirical trials explained by scientists continued to show that protospacer adjacent motif (PAM) specificity has a significant effect on the functionality of Cas9. When it comes to polycystic kidney disease (PKD), PAM sequence alignment with mutation hotspots in PKD1 and PKD2 becomes important in order to guide the CRISPR/Cas9 system-based correction to the disease-causing mutations. Such a use of computational models to predict the most appropriate PAM-based sequences to use in these loci then becomes crucial to optimise on target efficacy [30].

6.2 Theoretical Preparation of Lipid-Nanoparticles (LNP's)

LNPs can be described as a promising choice for CRISPR/Cas9 therapeutic delivery. Their biocompatibility, which has been demonstrated, and also the fact that they protect nucleic acid in the bloodstream, make LNPs appear particularly attractive as a method of intracellular delivery to a selected tissue. In polycystic kidney disease (PKD), one wishes to develop LNPs that will deliver CRISPR/Cas9 complexes to the kidneys, where disease-forming cysts originate. The LNP physicochemical properties (size, charge, and lipid composition) are adjustable to maximise their functionality in the sequestration by renal cells [26].

The dimension parameter is a focal determinant of lipid nanoparticles (LNPs) design. It has been shown that currently, the fine tuning of the diameter of a particle enhances the transfer of materials into cells as well as reduces the likelihood of clearance by the hepatosplenic region over a diameter of 50 nm-100 nm [11]. Surface charge on LNPs also has an authoritative impact on cellular intake: cationic, or positively charged, LNPs have greater attraction to negatively charged cellular membranes and are, therefore, a desirable tool in transduction of genes [20]. The ironical difference between the increased drug uptake and ensuing toxicity also requires an accurate dose-reduction regimen. A potential solution would be the addition of polyethylene glycol-lipids, which would reduce immune recognition, and extend circulating half life, rendering enhanced targeting by the renal system [17].

Encapsulability is a primitive computing structure. The relatively large CRISPR/Cas9 complex (3 to 4.2 kb CRISPR/Cas9 gene and 100 bp sgRNA) must need to be encapsulated safely within the lipid nanoparticles (LNPs) without losing the structural integrity. Lipid compositional design is the key process that determines the efficiency of the encapsulation process, as well as the stability of lipid-based nanoparticles (LNP), especially for the ratio of helper lipids, especially cholesterol and phosphatidylcholine. One accurate control of such parameters is essential in maintaining the stability of the CRISPR/Cas9 complex during circulation across the bloodstream and facilitating target intracellular delivery to the secondary targeted cells in the kidneys [12].

6.3 Electroporation Theory

Electroporation is one non-viral form of genetic delivery where transiently high electrical fields temporarily raise the permeability of the cell membrane to allow components of CRISPR/Cas9 to locate themselves inside the cell. Among these main strengths of electroporation is that electroporation can deliver large molecules, including CRISPR/Cas9 ribonucleoproteins (RNPs) into the cytoplasm or nucleus without a viral delivery system [18]. The electric field intensity, length of individual pulses and the total number of pulses used are calibrated to increase transfection efficiency and reduce cell damage, which is required to obtain successful electroporation.

The treatment of polycystic kidney disease (PKD) is a therapy with ex vivo electroporation and kidney cell retransplantation. The combination of predictive models of the plasma membrane behaviour, most notably the Smoluchowski equation, leads to a better understanding of the parameters of electroporation when its parameters are optimised to achieve optimal CRISPR delivery without major cellular damage [5]. More importantly, electroporation efficiency is cell-type dependent in terms of the membrane composition; combining electroporation with CRISPR may necessitate cell-type-specific pulse regimes that can achieve optimal CRISPR cargo uptake without causing apoptosis and overt necrosis in kidney cells [33].

Although the electroporation method has great potential in performing experiments at the preclinical stage, its application in performing experiments in vivo is limited. Electroporation is a biophysical process that creates short-lived cell-membrane permeabilization by high voltages pulses. Although these pulses can enable exogenous molecules to easily enter the target cells, they can also trigger unfavorable tissue damages. In this regard, electroporation is considered most suitable in situations where the tissue has to be kept ex vivo which would permit stringent permeabilization of the membrane without affecting any other underlying cellular structure. Subsequent theory can consequently determine the intersection of electroporation and lipid nanoparticles (LNPs) or non-invasive delivery modalities to produce productive in vivo CRISPR treatment [29].



A visual representation of the electroporation procedure, with kidney cells undergoing electroporation for CRISPR/Cas9 delivery. [Image taken from [42]]

6.4 Theoretical Models for Cell Culture and Animal Studies

The development of well-characterized cellular and animal models is the necessary step required to critically evaluate CRISPR/Cas9-based interventions on polycystic kidney disease (PKD). In vitro and in vivo systems have strong theoretical foundations, and this allows experimental design, such that experimental results are relevant to clinical studies.

In modern in vitro studies primary human kidney epithelial cells that have a mutation in PKD1 or PKD2, have been used as a cell model to study cystogenesis. Cellular 3-dimensional structures, opting for organoids, have increasingly been used to recapitulate the bio-complex kidney microenvironment and hence present a more accurate modelling platform through which to challenge a CRISPR-based gene alteration [7]. Computational modeling allows researchers to identify how certain CRISPR/Cas9 constructs and delivery methods will affect desired therapeutic outcomes, thus providing useful insights into the current therapeutic outcome [11].

The rodent models of polycystic kidney disease (PKD) harboring a mutation in Pkd1 or Pkd2 genes in the rodent models form an appropriate platform to test the in vivo effectiveness of CRISPR/Cas9. Through the combination of quantitative theoretical methods of predicting the efficiency of gene editing with pharmaco-kinetic analysis of delivery by lipid nanoparticle (LNP) or electroporation, researchers may already forecast the tissue distribution and functional ramifications of CRISPR/Cas9 delivery in renal tissue [37]. These models also allow longitudinal measures of effects, such as the damping of the cyst development and preservation of renal function, and note any off-target effects [39].

6.5 Assessment Techniques for Gene Editing Efficiency

To confirm CRISPR/Cas9-based gene-editing, one requires a stringent analytical pipeline that can confirm both that the intended target (gene) has undergone successful editing and that there has been no off-target effect. One of these methodologies involves the so-called next-generation sequencing (NGS), which allows accurate identification of the mutation of the desired locus and non-targeted sites [14]. Coming into contact with the treated and the untreated cells, researchers will be able to compare the genomic sequences of either of the cells to determine the efficacy of gene-edited variant correction in the PKD1 and PKD2 genes. And this methodology is intended to identify any unintended changes that can emerge alongside the explicit edit.

Another assessing system is associated with the incorporation of computational methods used to calculate off-target effects that are caused by the sgRNA sequence and context of the sequences on the genome. Probabilities of off-target cleavage events can be generated by the Advanced CRISPR Editing Software Platforms CRISPRiss [18] and CRISPResso [8] that also provide quantitative measurements of on-target precision. These models are the cornerstone of reducing the risk of unintentionally making changes in the genetic makeup, thereby reducing the possibility of negative results in medical aspects.

In order to evaluate the therapeutic effect, the size of the cyst as well as the number of cysts, along with clinical parameters including serum creatinine level and blood urea nitrogen level, are required. Improved functional status is further explained by the complementary histological analysis of renal specimens. Incorporating these parameters into the feasible theoretical frameworks relating the results of gene-editing interventions to the improvements of renal functions, the investigators will be able to adjust the protocol of the experiments and enhance the methodology of the clinical trials [11].

7. Theoretical Results

7.1 Anticipated Gene-Editing Outcomes

Some recent investigations have suggested that genetic manipulations of the PKD1 and PKD2 might be able to slow, and, maybe even stop the progress of the polycystic kidney disease. With the expression of functional polycystin-1 and polycystin-2 proteins, the CRISPR/Cas9 will be able to break out of the anomalous cellular signaling routes that stimulate excessive development and fluid retention in the renal

epithelial cells [9]. According to lab simulations, provided that even a relatively modest portion of cells is fixed, the resulting decrease in the growth of cysts may become visible.

As we go to determine whether CRISPR gene editing stands a chance in assisting individuals with polycystic kidney disease, the initial step is to learn the extent to which the process is effective within a controlled environment. Kidney organoids enter that. The mini-kidney structures that are grown in a dish are closely similar to human renal tissue and are able to observe what happens in the actual organ. Computer simulation of such organoids ought to indicate that once the defective genes are repaired using CRISPR, the quantity and size of cysts will be reduced [7]. Since the organoids allow us to observe architecture and cell growth in detail, it will most likely be sufficient to recapitulate the correct expression of the polycystin proteins in order to reinstate the normal operation of fluid through nephrons and reduce the hydrostatic pressure, which triggers cystogenesis.

Research indicates that with just a comparatively small percentage of afflicted epithelial cells being immobilized through gene editing, the total cyst burden can descend through an expansive part of the kidney. This is due to how segmented the organ is in itself, where, by fixing one patch, it creates a positive cascade effect on another area [37]. That is, disabling even lower fractions of malfunctioning alleles may elicit a clinically significant upswing, and hence that even incomplete gene fix may have significant therapeutic payoffs in PKD.

7.2 Expected Outcomes from Lipid-Nanoparticles (LNP's) Delivery

One of the greatest impediments when considering kidney diseases is polycystic kidney disease (PKD). At present, there is no actual cure, and one of the main objectives is to find a way that intervene without being invasive. The literature reinforces that the systemic delivery of CRISPR/Cas 9 with lipid-nanoparticle (LNP) formulations are promising with systemic delivery. As analyzed by bioinformatics, LNP conjugated to polyethylene glycol (PEG) with a size of 80 nm diameter forms a high likelihood of staying in circulation to reach the kidneys or avoid liver and spleen clearance. When there, they should attack the epithelial cells that form the renal tubules and cysts, leaving their CRISPR/Cas9 payload behind on their journey to the nucleus of the cell [20].

By modifying a lipid formulation (in this case, by adding cationic lipids), it is possible to enhance the selectivity of LNP to the negatively charged membranes of kidney cells, which additionally promotes uptake. Naturally, such an approach is associated with caveats, namely, the danger of immune clearance and the potential of renal toxicity upon repeated administration of LNPs. Recent recipes of computational toxicology are able to identify the dose point beyond which LNP-associated kidney distress begins to supersede the pharmacological advantage, demonstrating why the correct balance between efficacy and protection should be achieved through the integration of dosing and lipid design [12].

It is plausible that animal studies would reveal a discernible connection between the action of CRISPR/Cas9 in the renal tissues and a decrease in the burden of cysts. When the various LNP formulations are arranged end-to-end, researchers will be capable of selecting a setup that allows the drug to go to the kidneys and be absorbed in that part of the body, yet avoid the unwanted side effects in other organs.

7.3 Electroporation-based Delivery Efficiency

Electroporation is quickly becoming an alternative CRISPR/Cas9 delivery method, and experimental results in the past two years show that careful period-pulse manipulation can result in substantially increased cellular uptake with a huge reduction in off-target damage. By working on kidney tissues in culture, scientists demonstrate that meticulously adjusted electric shocks significantly optimize the quantity of CRISPR being delivered to renal epithelial cells [5]. Computer simulations indicate that moderate voltages in combination with a pulse range of 5 to 10 milliseconds will significantly open membrane pores, even though it has no long-term harmful effects on the cell [5].

Since the limited flow of the electrical current through the whole organ is limited by the morphology of the kidney, theoretical systems dictate that successfully performing the surgery will not be achieved in the entire organ but rather on specific restricted areas. Simulations revealed, when electroporation is applied in the areas where cysts are highly concentrated, CRISPR gene editing can be achieved with a better effect and without scarring the nearby healthy tissue. This method may reduce cysts and protect normal renal functioning as long as the electric charge is limited by the amounts that can kill cells directly [33].

Electroporation forms a potential complement to lipid nanoparticles (LNPs). Theoretically, LNPs released into the body, which administer CRISPR/Cas9 elements, can travel throughout the body, getting close to the kidneys. Targeted electroporation is an introduction of cell-specific channels into the plasma membrane that, after the application of electrical pulses, have formed pores. These resulting pores aid in translocation of the LNP cargo that is present in the extracellular environment into the intracellular environment contributing to the enhanced biologic delivery [26].

7.4 Expected Outcomes in Vivo Animal Models

The disease models in the murine family, which have mutations in Pkd1 or Pkd2 genes, represent the major experimental paradigm upon which the effective capability of the CRISPR/Cas9 gene-editing tool is tested. It is suggested that the renal cystic progression is expected to decrease considerably during a 6-to 12-month monitoring period after being delivered with the lipid nanoparticle (LNP) or the electroporation-based CRISPR. Analytical measures, e. g., serum creatinine and blood urea nitrogen (BUN) levels, are expected to become significantly better because of the reactivation of polycystin-1, polycystin-2 proteins and, as a result, the normal functioning of nephrons [39].

The data coming so far in the ongoing therapeutic trials are indicating that renal tissue histologic will indicate significant diminution in the number and the size of cysts in treated lines. At the same time, the increased percentages of regenerated

renal epithelial cells are expected to restore cellular polarity and reduce the frequencies of aberrant cell growth. These prognoses would agree with the results of previous gene-editing studies in animal models of inherited disease, which observed significant improvements in observable phenotypes after partial repair of diseased alleles [37].

Based on the theoretical models, therapeutic intervention-treated patients are expected to have a longer life span in comparison with the non-treated ones due to the slowing down of the PKD process through the therapy modality used. To determine the therapeutic value of CRISPR/Cas9 in patients with polycystic kidney disease (PKD) non-invasive imaging tools, specifically magnetic resonance imaging (MRI) and ultrasound, are applied to monitor the shrinking of the cysts. Using these modalities, a reduction in cysts is seen in real time.

7.5 Theoretical Long-Term Benefits and Risks

The persistence of the engineered genomic editing determines whether CRISPR/Cas9 will be a therapeutic modality in Polycystic kidney disease (PKD) in the long term. The persistent expression of the alteration would maintain cysts prevention and slow the progression of renal illness. As a result, the development of the disease would be retarded and even in those patients who ultimately need dialysis or kidney transplant, such development would be delayed, or even prevented. The suggested theoretical models assume that edited cells would go on dividing and the mutant population would gradually be replaced, thus maintaining kidney functions.

The use of CRISPR/Cas9 over extended periods poses different risks, especially to the occurrence of off-target genomic changes and immune-related problems. The potential off-target regions can be pre-selected with the use of bioinformatic tools, though the computational predictions will then have to be validated using animal models. Through repeated recognition by the adaptive or innate immune surveillance via activation with CRISPR/Cas9 engineered through liposomal nucleic-acid constructs (LNPs) or through electroporation, it may be possible to elicit directed responses against the Cas9 sequence encoded within the plasmid or the delivery vehicle. This activity can lead to uncontrolled inflammatory effects or alter the ability to provide the therapeutic effect [14]. To overcome these risks are the confirmation of theoretical concepts with in vivo trials and the preference for Cas9 variants that have diminished immunogenicity, and the use of transient vectors of delivery to limit immune detection.

8. Discussion

8.1 Interpretation of Theoretical Results

The existing theoretical frameworks hypothesize that the correction of the defects in PKD1 and PKD2 genes with the help of CRISPR/Cas9 technology might significantly reduce the rate of cyst formation in polycystic kidney disease patients. These gene restorations are expected to correct the sequelae to the biological dysregulations caused by the mutations in both genes that is, cell proliferation imbalance and fluid secretion perturbations, synonymous with polycystic kidney disease (PKD). The recent literature shows that the decrease in cyst formation measured in both the organoid and animal models is linked to clinically significant findings, namely the improvement of kidney functioning as well as the slowed down development of cystic nephropathy into end-stage renal disease [37].

The current theoretical framework used to assess the accuracy of gene-editing procedures, as evidenced by past analyses of genetic diseases like Duchenne muscular dystrophy (DMD) and sickle cell anemia [24, 3], also supports the idea that CRISPR/Cas9 can selectively modify the mutation of choice, when entwined with the ideally constructed delivery mechanism. Predictive evidence indicates that the therapeutic effect needed to treat polycystic kidney disease (PKD) could be attainable with incomplete corrective action of the lax allele, because full replacement of functional alleles might not be necessary to produce a clinically meaningful effect [7].

8.2 Comparison with Existing Literature

The evidence of the conducted experiments included in this work is largely consistent with the modern research that confirms CRISPR/Cas9 as the potential facilitator of the restoration of single-gene diseases. Research in cystic fibrosis (CF) has explained that only a small proportion of the cells expressing defective CFTR alleles need to be altered to restore the gene expression and lead to the resultant clinical benefits [31]. Similar results of researchers who tested CRISPR therapeutics using affected retinal tissues in vivo also verify the viability of working with organs and tissues that are especially challenging to access [25]. The current data show that, given its complex architecture and cystic pathology in polycystic kidney disease (PKD), the kidney is analogous in terms of genome editing, specifically, through CRISPR-based therapeutics, in the face of advanced delivery methods, including lipid nanoparticles (LNPs) and electroporation.

The nature of polycystic kidney disease (PKD) has its pathophysiological oddity, which should be mentioned clearly in the realm of monogenic disorders. Unlike the conditions that limit pathology to one organ or tissue alone, PKD is a systemic disorder that endangers the liver, the pancreas, and the cardiovascular system, among others [1]. This multisystem involvement raises pragmatic questions in the likelihood of CRISPR/Cas9-mediated gene editing for the conditions: would treating the disease result in improved extra-renal phenotype, or would the effect be limited to the renal tissue? Gene reengineering investigations into the polygenic diseases, notably Huntington disease and amyotrophic lateral sclerosis (ALS), give insights that in-depth modification in as many affected tissues as possible is a logistical and technical challenge [38]. Therefore, the situation of PKD requires additional theoretical and empirical research to prove that CRISPR/Cas9 might effectively contribute to addressing the complex extra-renal manifestations characteristic of the disease.

8.2.1 Case Studies

Case Study #1 [45]**:** CRISPR/Cas9 for Sickle Cell Disease and Beta Thalassemia

Conducted By: Dr. Hayder Frangoul, St. Jude Children's Research Hospital, Tennessee, in collaboration with Vertex Pharmaceuticals and CRISPR Therapeutics.

Published In: *New England Journal of Medicine* (DOI: 10.1056/NEJMoa2031054)

Overview: This study focused on the CRISPR /Cas9 use to treat genetically diagnosable bleeding problems, such as Sickle Cell Disease (SCD) and Beta Thalassemia. The patients hematopoietic stem cells (HSCs) were transduced with lentiviral vectors expressing a mutant protein to interfere with the **BCL11 A** gene restoring fetal hemoglobin (HbF). Such modified HSCs were subsequently reintroduced back to patients following an administration of chemotherapy to kill the untreated cells.

Results

a) Beta Thalassemia:
- About 15 patients receive edited autologous CRISPR hematopoietic hematopoietic stem cells.
- The results indicated that 12 patients out of 15 were transfusion-independent after 12 months of follow up indicating a reversal in their blood functions to normal.
- The level of median hemoglobin went up to 11.5 g/dL as compared to 7.6 g/dL before treatment.

b) Sickle Cell Disease:
- One hundred percent of all patients who had undergone the treatment had gone a year without experiencing crises (and some stated that they had completely stopped pain crises).
- The HbF of some of the patients was likewise activated and its contribution towards the reduction of red blood cell sickling was also realized.
- The medical examinations showed an augmented hemoglobin level and the number of red blood cells as well as removal of vaso-occlusive crises.

c) Key Observations:
- Transfusions were not necessary to patients with Beta Thalassemia that was treated.
- In the case of Sickle Cell Disease, the number of pain crises was significantly decreased and patients found the improvement of the quality of life dramatic.
- Long-term follow up was given to verify long-term utility of CRISPR-edited cells capable of chronic expression of fetal hemoglobin.

Case Study #2 [44]**:** CRISPR in HIV Treatment

Conducted By: Dr. Kamel Khalili, Lewis Katz School of Medicine, Temple University, collaborating researchers from Temple University and UCLA.

Published In: *Gene Therapy* (DOI: 10.1038/s41434-023-00410-4)

Overview: In the study, scientists focus on the use of CRISPR/Cas9 to eliminate HIV proviral DNA in infected cells of non-human primates (NHPs). The paper was designed to explore the potential of using CRISPR as a solution to HIV specifically by targeting and destroying the dormant viral reservoirs, which is a major hitch in terms of elimination of HIV.

Process and Methodology
Their experimental group exploited the AAV (adeno-associated virus) vectors to introduce CRISPR/Cas9 components into HIV-latently infected cells targeting their long terminal repeat (LTR) of the Gag viral genome. They were in vivo delivered in rhesus macaques that had been infected with simian immunodeficiency virus (SIV), an HIV-related virus. The viral DNA removal and the immune response was evaluated based on the multiple CRISPR treatments over several months.

Results:
a) **Viral Reservoir Reduction:** The CRISPR therapy was effective at deleting over 85 percent of the SIV proviral DNA in different essential organs, including the lymph nodes, the spleen, and the peripheral blood mononuclear cells (PBMCs). After a few rounds of CRISPR therapy, the macaques who were under treatment were shown to have a significant decline in the viral loads and further the SIV could not be traced in the plasma up to 6 months.
b) **Functional Cure Indicators:** The study showed that the treated animals never required any further antiretroviral therapy (ART), their inability to show any detectable viral DNA after treatment represented a potential functional cure. Moreover, the experiment discovered that the macaques immune systems responded favorably in eliminating virus infected cells without triggering harmful immune responses.
c) **Safety Profile and Immune Reactions:** There was no severe immune-mediated and inflammatory response observed on the treated animals, implying that CRISPR could be applied without side effects of cytokine storm and other severe adverse effects. No signs of the unintended mutation or DNA damage in non-targeted cells were detected by the histopathological analysis of tissues.

8.3 Technical Challenges

The improvements in the CRISPR/Cas9 system have created positive buzz on the potential of the technology in the treatment of polycystic kidney disease (PKD). However, a number of serious technical obstacles do exist. The most notable of them consists of the issue of off-target editing, where the CRISPR nuclease can unintentionally cut the DNA segments that fall outside of the desired therapeutic locus and, in such a manner, generate unforeseen and, in exceptional circumstances, cancerous mutations [8]. The bioinformatics algorithms used in estimating off-target likelihood, though as computational models are invaluable sources of information as far as risk assessment is concerned, they can only act as stop-gaps; in vivo validation is imperative in curtailing these risks. Furthermore, identified in recent research, improvements in guide RNA design, such as truncation or alteration, can reduce off-target effects [36]; however, these improvements will require re-adjustment on a case-by-case basis to PKDs to attain the best possible results.

Targeted delivery of the nanoparticles is also one of the main challenges in the field of engineering. Even though lipid

nanoparticles (LNPs) are effective in a variety of body systems, most notably the liver and the lungs, theoretical pharmacokinetic approaches indicate that targeting the renal system will introduce new complexities [20]. The penetration of nanoparticles into the organs may be hindered by the high degree of filtration of the kidneys, the thick cystic structure of polycystic kidney disease (PKD). Directed delivery Electroporation offers a way of delivering therapeutic cargo that overcomes some biological structuring barriers, and can, therefore, allow a more precise administration of the CRISPR/Cas9 complex to a targeted tissue. However, this method is associated with some risks like tissue injury and immune stimulation, and thus has to be controlled carefully [5].

The scaling ability is another technical requirement of the translation of CRISPR/Cas9-based gene editing for polycystic kidney disease (PKD). Theoretical investigations conducted at large suggest that disease progression is decelerated in the case of partial destruction of the tubular epithelia in the event of the afflicted tissue representing an insignificant percentage of the overall organism. However, being a progressive, chronic disease, PKD requires regular or, in the majority of cases, lifetime treatment. It would be impractical to rely on repeated in vivo delivery of CRISPR/Cas9, as that would reduce therapeutic efficacy, although such a paradigm would probably induce immune responses and genetic accumulated edits with time [4]. Immune rejection A more significant complication in the scenario of genome editing is the recurrent immune rejection: repeated exposure to Cas9 can potentially lead to subsequent immunogenic rejection [2].

8.4 Ethical Considerations

The use of CRISPR/Cas9 technology on humans provides a range of ethical considerations, primarily when it comes to changing the germline. Though the discussed scenarios here include editing of somatic cells and, as such, altering only the treated person, any off-target mutation may precondition hereditary changes of much greater magnitude. The emergence of ethical discussions on the application of CRISPR in human embryos [13] points to the importance of situations where gene-editing technologies have to be applied with care and full awareness of associated risks. The scenario, however, is likely to remain the same in the example of the polycystic kidney disease (PKD), which is largely an adult-onset disease; the mere theoretical chance of making unwanted germline changes, however, will continue to haunt the prospect.

The emergence of the CRISPR/Cas9 pharmaceuticals poses a number of urgent ethical issues related to fair distribution. Since these gene-editing treatments will probably be very costly, this intervention would be unavailable to patients in low-income environments or within limited healthcare coverage [15]. As polycystic kidney disease (PKD) is among the most common diseases, the implementation of gene-editing-based approaches would broaden the healthcare gap, which already exists, by limiting the treatment only to people who can afford the intervention. A series of econometric studies reveal that the implementation of expensive gene therapies tends to create a two-layered level of delivery where a limited group of people (those who are economically stable) get access to futuristic intervention, whereas the rest of the patients continue to depend on the existing, and comparatively less effective interventions. These inequities will be crucial to counter when CRISPR-based approaches to the treatment of PKD and other hereditary disorders become clinically feasible.

8.5 Safety and Long-Term Effects

The safety of the use of CRISPR/Cas9 therapy over the long run on polycystic kidney disease (PKD) is a top-level issue. Many hypothetical scenarios indicate that continued monitoring of outcomes of gene-editing procedures will be necessary to allow the identification of late-onset problems, such as cancer development and immune-related sequelae [14]. Another potentially relevant means of alleviating such risks, however, could be inducible Cas9-based strategies, systems which can be reversibly activated and inactivated. The systems will reduce the rate of off-target mutations because they reduce the number of hours that Cas9 is working, thus limiting the window of cleavage [40]. Even though engineering this modification sustains high levels of gene correction, nonetheless, technical limitations are established: activation and termination need to be both coordinated and reproducible within the relevant organ microenvironment.

The current debacle around repeated exposure to the genetic-editing complex Cas9 is its immunogenicity when used repeatedly. Experimental evidence shows that animal models exhibit a specific immune response towards Cas9 and therefore raises critical considerations on the realisation of sustained or frequent applications in treatments [2]. Academic proposals have thus postulated either in the creation of a Cas9-mutation with diminished immunogenicity or through the use of a transient delivery mechanism over biological immunity, including mRNA and ribonucleoprotein complexes, although both these hypotheses would require experimental validation [28].

9. Conclusion

The exploration of using the CRISPR/Cas9 technology to target PKD through genes PKD1 and PKD2 to combat Polycystic Kidney Disease is what this paper is based upon. The study developed a theoretical framework that illustrates the possibility of having an avenue towards dealing with genetic aspects of PKD through CRISPR/Cas9, since it can present the potential in precisely editing the mutations within those genes to cut down cyst formations and improve renal functions. Focused interventions have the potential to surpass traditional paradigms of polycystic kidney disease (PKD) which are traditionally focused on symptomatic management, and implement methods of treatment that are clinically viable, curative in nature.

Available data in the literature indicate that the approach of optimization of delivery systems, especially lipid nanoparticles and electroporation, can increase the precision and efficacy in the city tissue gene editing. The positive outcomes of animal models, like the decrease in the number of cysts and the increase in renal functioning, confirm the findings that CRISPR/Cas9 can be operationally effective

even with a relatively low percentage of real renal cells with genetically corrected specialists [7]. This data confirms existing data on the efficacy of CRISPR/Cas9 in treating other genetic disorders, and therefore, in such directions as the treatment of polycystic kidney disease, it will be appropriate to use a similar approach.

Recent studies explain how numerous challenges are still ahead before CRISPR-Cas9 renal therapy can become clinically viable. There exist expressed fears of off-target genetic modification that might give rise to side-effects, e. g., the development of tumors, which current advances in guide RNA design and bioinformatic analysis aim to prevent [8]. Moreover, effective transfer of the CRISPR-Cas9 complex to the kidney tissue would also be a technical issue due to a lack of knowledge regarding the kinetics of CRISPR-Cas9 transport and the complex physiology of the kidney, at least when cystic disease is present [20].

The potential use of the CRISPR-based type of gene-editing therapy in terms of treating PKD brings up a few ethical concerns. Top among them is fair accessibility: genetic treatments should be made accessible to a wide section of society. Although not the immediate clinical concern of the study, germline editing should be subjected to scrutiny as CRISPR-based medicine advances, because it poses implications of systemically egregious proportions for the human species in the long run [15]. The lack of access may worsen any pre-existing social disparities, as well as lead to health disparities.

In summary, current studies provide genetically-based explanations on polycystic kidney disease (PKD), and require a multi-pronged approach that integrates genetic engineering, delivery sciences, and ethical analysis in case these findings should be turned into clinically relevant solutions. Further research efforts ought to be focused on the maximization of CRISPR-based protocols, choice of suitable delivery capsules, and the challenge of the ethical challenges inherent in gene editing. As the scientific community continues to explore fully the vast possibilities of CRISPR, it is important to maintain a watchful eye on the effects it is having to ensure such a development continues to remain within reach and risk-free among every person being affected by PKD and other hereditary diseases.

References

[1] Bergmann, C., et al. (2018). Polycystic kidney disease: Insights into pathogenesis and novel therapeutic options. Clinical Kidney Journal, 11 (3), 210-226. https: //doi. org/10.1093/ckj/sfx135
[2] Chew, W. L., Tabebordbar, M., Cheng, J. K., Mali, P., Wu, E. Y., Ng, A. H.,. . . & Church, G. M. (2016). A multifunctional AAV-CRISPR-Cas9 and its host immune response in vivo. Nature Methods, 13 (10), 868-874. https: //doi. org/10.1038/nmeth.3993
[3] Dever, D. P., et al. (2016). CRISPR/Cas9 β-hemoglobin gene editing in patient-derived stem cells. Nature, 539 (7628), 220-225. https: //doi. org/10.1038/nature20134
[4] Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346 (6213), 1258096. https: //doi. org/10.1126/science.1258096
[5] Escoffre, J. M., et al. (2015). What is (still not) known of the mechanisms by which electroporation induces gene transfer and expression?. Molecular Biotechnology, 57 (3), 457-472. https: //doi. org/10.1007/s12033-014-9829-3
[6] Esvelt, K. M., Smidler, A. L., Catteruccia, F., & Church, G. M. (2014). Concerning RNA-guided gene drives for the alteration of wild populations. eLife, 3, e03401. https: //doi. org/10.7554/eLife.03401
[7] Freedman, B. S., Lam, A. Q., Sundsbak, J. L., Iatrino, R., Su, X., Kottgen, A.,. . . & Bonventre, J. V. (2015). Reduced ciliary polycystin-2 in induced pluripotent stem cells derived from polycystic kidney disease patients with PKD1 mutations. Journal of the American Society of Nephrology, 26 (10), 2401-2412. https: //doi. org/10.1681/ASN.2014040385
[8] Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology, 31 (9), 822-826. https: //doi. org/10.1038/nbt.2623
[9] Gallagher, J. T., et al. (2020). CRISPR/Cas9 targeted gene therapy for autosomal dominant polycystic kidney disease. Journal of Nephrology, 29 (3), 219-225.
[10] Gaj, T., Sirk, S. J., Shui, S. L., & Liu, J. (2016). Genome-Editing Technologies: Principles and Applications. Cold Spring Harbor perspectives in biology, 8 (12), a023754. https: //doi. org/10.1101/cshperspect. a023754
[11] Guimaraes, P. P., Zhang, R., Spektor, R., Tan, M., Chung, A., & Shi, J. (2019). Lipid Nanoparticles Encapsulating Cas9 mRNA for the Treatment of Kidney Disease. Science Advances, 5 (4), eaaw2029. https: //doi. org/10.1126/sciadv. aaw2029
[12] Hajj, K. A., Ball, R. L., Deluty, S. B., Singh, S. R., Strelkova, D., Knapp, C. M., & Whitehead, K. A. (2019). Lipid nanoparticles for gene editing: applications in cancer therapy and beyond. ACS Nano, 13 (6), 6438-6456. https: //doi. org/10.1021/acsnano.9b00857
[13] He, J., et al. (2018). Genome-edited babies: what went wrong and what could go wrong. Nature Reviews Molecular Cell Biology, 19 (11), 675-688. https: //doi. org/10.1038/s41580-018-0065-1
[14] Hsu, P. D., Lander, E. S., & Zhang, F. (2013). Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157 (6), 1262-1278. https: //doi. org/10.1016/j. cell.2014.05.010
[15] Jasanoff, S., Hurlbut, J. B., & Saha, K. (2019). CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology, 35 (1), 25-36.
[16] J. Sieben, C. & C. Harris, P. (2023). Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing. ncbi. nlm. nih. gov
[17] Kauffman, K. J., et al. (2015). Optimization of lipid nanoparticle formulations for mRNA delivery to immune cells. Molecular Therapy, 23 (9), 1307-1315.
[18] Kim, S., et al. (2017). Enhanced CRISPR/Cas9 delivery through non-viral electroporation systems for gene

therapy applications. Scientific Reports, 7, 1696. https: //doi. org/10.1038/s41598-017-01966-2
[19] Koupepidou, P., et al. (2010). PKD genetics and polycystin function: Understanding the molecular mechanisms. Clinical Nephrology, 73 (5), 316-324.
[20] Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2018). The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 13 (6), 570-578. https: //doi. org/10.1038/s41565-018-0245-0
[21] Li, L., et al. (2020). Design and optimization of guide RNAs in CRISPR/Cas9 systems to mitigate off-target effects in therapeutic applications. Nature Communications, 11 (1), 1054. https: //doi. org/10.1038/s41467-020-14788-2
[22] Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018). Delivering CRISPR: a review of the challenges and approaches. Drug Delivery, 25 (1), 1234-1257. https: //doi. org/10.1080/10717544.2018.1474964
[23] Liu, Q., et al. (2021). Decoding CRISPR's potential in genetic disorders: Structure, function, and applications. Annual Review of Genetics, 55 (1), 175-198.
[24] Long, C., et al. (2016). Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, 351 (6271), 400-403.
[25] Maeder, M. L., et al. (2019). Development of CRISPR/Cas9 for efficient therapeutic gene editing of RPE65 in retinal disorders. Science, 364 (6440), 117-120.
[26] Miller, J. B., & Harrison, M. J. (2018). Optimizing electroporation for delivery of CRISPR/Cas9 into renal cells. Biotechnology and Bioengineering, 115 (3), 654-664.
[27] Mohammadian Farsani, T., et al. (2024). Gene-editing advancements in the treatment of polycystic kidney disease. Journal of Nephrology Research, 41 (2), 81-92.
[28] Nelson, C. E., et al. (2019). Long-term evaluation of AAV-CRISPR genome editing in muscular dystrophy. Nature Medicine, 25 (3), 427-432.
[29] Perrin, A., et al. (2020). Cellular models of polycystic kidney disease: Advancing therapeutic development. Kidney International, 98 (4), 718-730.
[30] Ran, F. A., et al. (2013). Genome engineering using the CRISPR-Cas9 system. Nature Protocols, 8 (11), 2281-2308.
[31] Ribeiro, C. M., et al. (2018). Correction of defective CFTR function in intestinal organoids by CRISPR-based gene editing. Journal of Clinical Investigation, 128 (6), 2560-2565.
[32] Shan, Q., et al. (2018). Directed genome editing in rice and wheat with a CRISPR/Cas system. Nature Biotechnology, 31 (8), 686-688.
[33] Shirley, M., et al. (2020). *32. Shirley, M. K., et al. (2020). Evaluating the impact of electrical parameters on electroporation efficiency for kidney cell therapy. Biotechnology and Bioengineering, 117 (2), 302-316.
[34] Slaymaker, I. M., et al. (2016). Rationally engineered Cas9 nucleases with improved specificity. Science, 351 (6268), 84-88. https: //doi. org/10.1126/science. aad5227
[35] Tavakolidakhrabadi, A., et al. (2024). CRISPR/Cas9 advances in targeting polycystic kidney disease. Clinical Kidney Journal, 37 (1), 12-18.
[36] Tsai, S. Q., & Joung, J. K. (2016). Defining and improving the genome-wide specificities of CRISPR/Cas9 nucleases. Nature Reviews Genetics, 17 (5), 300-312. https: //doi. org/10.1038/nrg.2016.28
[37] Wu, J., et al. (2018). CRISPR-Cas9 correction of a PKD1 mutation in a mouse model of polycystic kidney disease. Journal of Clinical Investigation, 128 (3), 1056-1069. https: //doi. org/10.1172/JCI99285
[38] Yang, S., et al. (2019). Genome-wide CRISPR screen identifies genes essential for polycystin complex function in renal cyst formation. Nature Communications, 10 (1), 1-14. https: //doi. org/10.1038/s41467-019-09737-9
[39] Yu, S., et al. (2020). Long-term efficacy of CRISPR-Cas9 gene editing for polycystic kidney disease in mice. Nature Medicine, 26 (7), 1040-1047. https: //doi. org/10.1038/s41591-020-0831-x
[40] Zetsche, B., et al. (2015). A compact Cas9 orthologue for genome editing with reduced immunity. Nature, 529 (7587), 541-545. https: //doi. org/10.1038/nature16526
[41] Mohapatra, S., & Ghosh, D. S. (2018). Playing with DNA. *Journal of Clinical Genetics and Genomics*, *1* (2). https: //www.pulsus. com/scholarly-articles/playing-with-dna-4699. html
[42] Hassan, Ali & Alshawi, Nada & Bassim, Elaf & Alkaisy, Shahad. (2020). GENE THERAPY, FUTURE APPROACH FOR TREATMENT: A REVIEW. Plant Archives.20.5615-5621. Hassan, Ali & Alshawi, Nada & Bassim, Elaf & Alkaisy, Shahad. (2020). GENE THERAPY, FUTURE APPROACH FOR TREATMENT: A REVIEW. Plant Archives.20.5615-5621.
[43] Ghosh, D. (2024, July 24). Chandipura Virus Symptoms: Outbreak Leads To Increase In Death Toll, Signs To Watchout For. Times Now. https: //www.timesnownews. com/health/chandipura-virus-symptoms-outbreak-leads-to-increase-in-death-toll-signs-of-the-condition-to-watchout-for-article-11197682
[44] POLYCYSTIC KIDNEY DISEASE – AceLink Therapeutics. (2024). Acelinktherapeutics. com. https: //acelinktherapeutics. com/polycystic-kidney-disease/
[45] Burdo, T. H., Chen, C., Kaminski, R., Sariyer, I. K., Mancuso, P., Donadoni, M., Smith, M. D., Sariyer, R., Caocci, M., Liao, S., Liu, H., Huo, W., Zhao, H., Misamore, J., Lewis, M. G., Simonyan, V., Xu, E. Y., Cradick, T. J., Gordon, J., & Khalili, K. (2023). Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates. *Gene Therapy*, 1–10. https: //doi. org/10.1038/s41434-023-00410-4
[46] Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., de Montalembert, M., Rondelli, D., & Sharma, A. (2020). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. *New England Journal of Medicine*, *384* (3). https: //doi. org/10.1056/nejmoa203105.